Sterile meropenem trihydrate is processed through low-temperature dissolution in Water for Injection at 2–8 °C to reduce hydrolytic opening of the β-lactam ring before the addition of anhydrous sodium carbonate. The formulation addition ratio in the 1 g presentation is meropenem trihydrate equivalent to 1000 mg meropenem and 90.2 mg sodium carbonate per vial; the 500 mg presentation carries 45.1 mg sodium carbonate. This ratio is fixed to maintain a reconstituted pH of 7.3–8.3 and to suppress degradation dimer formation after the addition of 20 mL Water for Injection. Compliance for sterile FDF manufacture is anchored to USP <71> sterility, USP <85> bacterial endotoxins, USP <921> Method I water content, and USP <788> particulate matter, with the filling suite operating under EU GMP Annex 1:2022 aseptic processing and ISO 14644-1:2015 Grade A/ISO 5 unidirectional airflow. The downstream production sequence uses a jacketed stainless-steel compounding vessel to dissolve the API at 2–8 °C, followed by sterile filtration through a 0.22 µm PVDF membrane and aseptic filling into 50 mL Type I borosilicate vials with a target fill volume of 20.0 mL. Partial stoppering precedes lyophilization on shelf hardware with a condenser temperature at or below -60 °C, chamber pressure maintained between 130 Pa and 260 Pa, and shelf temperature held below the collapse temperature of the formulation during primary drying; typical cycles run 40–60 h and achieve cake moisture below 1.0%. Batch-to-batch variance in residual moisture from 0.3% to 0.8% is observed depending on API crystal habit, sodium carbonate particle-size distribution, and vial heat-transfer uniformity. Container closure integrity is confirmed using USP <1207> methodology before release. The terminal finished product is a lyophilized powder for solution for injection, single-dose vial, reconstituted to 50 mg/mL and further diluted in 0.9% sodium chloride or 5% dextrose for intravenous infusion. Oral tablet, capsule, and granule presentations are not registered for meropenem or imipenem because of negligible gastrointestinal absorption and instability in gastric fluid; published data for a therapeutically equivalent oral FDF is limited.

When Does Imipenem Require a Renal Dehydropeptidase Inhibitor in Sterile FDF Processing?

Imipenem monohydrate is not formulated as a monotherapy FDF because renal dehydropeptidase-I rapidly hydrolyzes the intact β-lactam ring in vivo; the downstream FDF route therefore fixes imipenem with cilastatin sodium at a 1:1 active ratio. In the 500 mg/500 mg presentation, the vial contains imipenem monohydrate equivalent to 500 mg imipenem, cilastatin sodium equivalent to 500 mg cilastatin, and 20 mg sodium bicarbonate per vial; the 250 mg/250 mg presentation scales proportionally. Manufacturing is performed as an aseptic dry powder fill rather than terminal steam sterilization because the imipenem β-lactam ring degrades under moist heat; the filling core is held at 30% relative humidity or below. Blending and transfer occur in a rigid isolator or restricted-access barrier system certified to ISO 14644-1:2015 Class 5 with unidirectional airflow, and the blend is charged into a rotary powder filler with 6–12 dosing stations. Fill weight uniformity is controlled according to USP <905> uniformity of dosage units and Ph. Eur. 2.9.40, while water content is tested by USP <921> Method I. Static charge and powder segregation are reduced by low-shear tumble blending for 15–30 min, and the hopper is fitted with a grounded 316L stainless-steel contact surface to prevent adhesion. The terminal product is a sterile powder for solution for infusion, single-dose vial, reconstituted to 50 mg/mL imipenem and then diluted in 0.9% sodium chloride or 5% dextrose; after constitution, the solution is used within 4 h at room temperature or 24 h under refrigeration at 2–8 °C.

Co-lyophilization of meropenem with the cyclic boronic acid β-lactamase inhibitor vaborbactam yields a fixed-dose single-vial product indicated for complicated urinary tract infections caused by carbapenem-resistant Enterobacterales. The addition ratio is 2000 mg meropenem and 2000 mg vaborbactam per 100 mL vial, with no bacteriostatic preservative; the bulk solution is prepared at 2–8 °C to limit meropenem degradation during dissolution and filtration. Compliance for this route includes USP <71> sterility, USP <85> bacterial endotoxins, ICH Q3D elemental impurity limits, and Ph. Eur. 2.6.30 for nitrosamine control in the starting materials; the aseptic process is conducted under EU GMP Annex 1:2022 and ISO 14644-1:2015 Class 5 conditions. Production begins with dissolution in Water for Injection, adjustment of pH toward the approved formulation target, sterile filtration through 0.22 µm filters, and filling into 100 mL Type I glass vials. Lyophilization shelf hardware is programmed to hold the product below the collapse temperature during primary drying; chamber pressure is maintained between 130 Pa and 260 Pa, and cake moisture is controlled to below 1.0%. Reconstitution requires 20 mL of 0.9% sodium chloride to produce 100 mg/mL meropenem, followed by transfer to a 100 mL bag for infusion. The terminal product is a lyophilized powder for solution for injection, single-dose vial; reconstituted solution is for immediate use unless a continuous-infusion stability protocol is validated. Published data for extended room-temperature stability of this specific combination after reconstitution is limited.

Hospital Pharmacy Admixture Stability Limits for 20 mg/mL Meropenem Infusion Bags

Downstream admixture of meropenem for inpatient intravenous use requires aseptic reconstitution of a 1000 mg vial with 20 mL Water for Injection and transfer into a 50 mL or 100 mL polyolefin or PVC-free infusion bag containing 0.9% sodium chloride, producing a nominal concentration of 20 mg/mL. The dilution ratio at this stage is 1 g meropenem per 50 mL diluent, with adult daily doses of 3–6 g administered in divided infusions ranging from 500 mg to 2 g per bag. The process is governed by USP <797> for sterile compounding and performed in an ISO 14644-1:2015 Class 5 biological safety cabinet or compounding aseptic isolator; personnel use sterile gloves, gowns, and syringe adapters that do not introduce particulate contamination. After reconstitution, the solution is visually inspected against USP <790> visible particulates, and the final bag is labeled with a refrigerated storage limit of 24 h at 2–8 °C. Published room-temperature stability for 20 mg/mL meropenem in 0.9% sodium chloride supports a use window of approximately 4 h at 20–25 °C; beyond this interval, hydrolytic degradation products can exceed impurity limits specified in the applicable pharmacopoeial monograph. The terminal product is a ready-to-infuse intravenous bag for hospital inpatient use, with the bag material documented as copolyester, polyolefin, or PVC-free to minimize sorption of meropenem and plasticizer release.

If Continuous Infusion via Elastomeric Pump Is Required, Reservoir Temperature Governs Shelf Life

The outpatient parenteral antimicrobial therapy route for meropenem uses 6 g meropenem diluted in 240 mL of 0.9% sodium chloride to a concentration of 25 mg/mL, filled aseptically into a single-use elastomeric pump reservoir. The addition ratio is 25 mg meropenem per 1 mL diluent; a 120 mL reservoir carries 3 g meropenem, while the 240 mL reservoir carries 6 g. Home infusion pharmacy production is governed by USP <797>, ISO 28620:2010 for elastomeric infusion devices, and the ASHP Guidelines on Home Infusion Pharmacy Services 2021. The filling process is conducted in an ISO 14644-1:2015 Class 5 compounding aseptic isolator, with the final device inspected for air bubbles, free-flow accuracy, and reservoir integrity; the fill volume tolerance is specified by the device manufacturer and is typically ±10% of nominal capacity. Temperature during administration is the process variable that limits clinical viability: at ambient wear temperature of 30–32 °C, published stability data indicate that meropenem degradation accelerates beyond 12 h, so the pump is filled under refrigerated conditions and the patient is instructed to keep the reservoir between 20 °C and 25 °C using a cold pack or insulated pouch. The terminal product is an elastomeric pump device for 24 h continuous intravenous infusion, typically delivering 10 mL/h for a 240 mL reservoir; any residual solution after the prescribed dwell time is discarded.